Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug inhibits angiogenesis: the formation of new blood vessels. Angiogenesis, in the context of cancer, enables blood supply to tumors, resulting in tumor growth and spread.
Cediranib is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
National Institutes of Health website has a list of 65 Cediranib clinical trials. Some of these studies are recruiting new patients. One of these studies, which was opened on 18 July 2009, recruits Alveolar Soft Part Sarcoma Patients: “Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma”. Currently, this is one of the most promising known treatments for ASPS.
You can read encouraging comments about Cediranib from ASPS patients using the drug since September 2007 in the appropriate section of our forum.
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)